Therapeutics

3,684 Companies

Access all companies

Find technology partners quickly.

Spotfolio tracks over one million companies in technology industries.

There are 3,684 companies in the field of Therapeutics on spotfolio that produce or deliver products, that utilize or research technologies or that are otherwise engaged in topics such as Clinical, Therapeutic, Patients, Treatment, Therapy, Drug, Dr, Disease .

Start-ups (640)

Early-stage companies (950)

Established companies (1,626)

The majority of these companies is located in the following countries.

United States (2,306)

United Kingdom (187)

Canada (131)

Germany (107)

Example Companies

Find companies in your area

Cerebral Therapeutics Cerebral Therapeutics, Inc.

established

Access

  • Technologies
  • Core data such as location, employees, revenues
  • Similar and peer companies
  • and more

Web Quotes

patient has been enrolled in a Phase 2b study of intracerebroventricular drug delivery of the anti-seizure medication CT-010 in patients with medically ...

system for continued investigation of the safety and effectiveness of the therapy. Read Full Article November 10, 2020 Cerebral Therapeutics Appoints Stephen ...

Distill AURORA, Colo.--(BUSINESS WIRE)--Cerebral Therapeutics, Inc., a clinical-stage pharmaceutical company developing innovative treatments for neurological

anti-seizure therapy through implantation of an intracerebroventricular drug delivery system for drug-resistant epilepsy AURORA, Colo., June 1, 2020 - Cerebral Therapeutics ...

Therapeutics publishes the first human study to test a long-term anti-seizure therapy through implantation of an intracerebroventricular drug delivery system

medications (anticonvulsants, antiepileptic drugs) are the first line of treatment. Oral medications are not effective for 30% of epilepsy patients. Patients ...

treatment. Oral medications are not effective for 30% of epilepsy patients. Patients who are resistant to conventional orally administered medications

company’s development activities are focusing towards providing an alternative treatment to those patients who continue to have seizures despite taking conventional

Management Company Advisers - Refractory Epilepsy Background Neurologic Disease Burden Solution - News and Events - Investors - About Cerebral Therapeutics™/

Management Company Advisers - Refractory Epilepsy Background Neurologic Disease Burden Solution - News and Events - Investors - About Cerebral Therapeutics™/

Cerebral Therapeutics - Company Background Board of Directors Company Management Company Advisers - Refractory Epilepsy Background Neurologic Disease

Cerebral Therapeutics - Company Background Board of Directors Company Management Company Advisers - Refractory Epilepsy Background Neurologic Disease ...

Cerebral Therapeutics™ Raises Series A Extension Financing to Advance Clinical-Stage Drug Device Combination Therapy to Phase 3 Readiness for Adult Refractory

focused on Class III devices and drug-device combination products in the therapeutic areas of movement disorders and epilepsy. Prior to joining Cerebral Therapeutics™

positions in multiple pharmaceutical and biotech companies in a wide range of therapeutic areas, resulting in over a dozen approved drugs and multiple company acquisitions

Investors/ Solution: Enhance the effectiveness of anti-epileptic therapy for patients who do not respond to oral medications through regional drug delivery into

Access

  • Technologies
  • Core data such as location, employees, revenues
  • Similar and peer companies
  • and more

Web Quotes

Discovery Partners Announces Positive Results from Phase 1 Studies of Cognition Drug Candidate, BPN14770 December 19, 2016 BPN14770 shown safe and orally bioavailable

- Publications - Clinical Trials - News - Contact FDA Grants Orphan Drug Designation for Tetra Discovery Partners’ BPN14770 for the Treatment of Fragile

Europe and in several other potentially significant markets for the new therapy.” About BPN14770 BPN14770 is a novel therapeutic agent that selectively

prevalence and increasing economic impact, the search for a disease modifying therapy has proved elusive. Drugs that address cognitive impairment, such as cholinesterase

BPN14770 to Provide Therapeutic Benefit in Fragile X Syndrome - Daily treatment with BPN14770 in a mouse Fragile X model showed reduced hyperarousal, improved

Partners’ BPN14770 to Provide Therapeutic Benefit in Fragile X Syndrome Daily treatment with BPN14770 in a mouse Fragile X model showed reduced hyperarousal, improved

Clinical Trials on Alzheimer’s Disease Meeting (CTAD) Study Shows that TNF Blocking Agents Reduce Risk of Alzheimer’s Disease in Patients with Rheumatoid ...

Presentation of Data from Retrospective Population-Based Study of 56 Million Patients at the 12th Clinical Trials on Alzheimer’s Disease Meeting (CTAD) Study

potential cognitive benefit in a rare orphan disease, Fragile X Syndrome, and in Alzheimer’s Disease, a disease that affects upwards of 5 million elderly ...

Partners - Careers - Science - Our Focus - Pipeline - Publications - Clinical Trials - News - Contact - Company - Leadership - Milestones - Partners

Clinical Trials - News - Contact Discovering New Medicines Tetra Therapeutics Announces Positive Topline Results from Phase 2 Study of BPN14770 in

Clinical Trials - News - Contact New Preclinical Research Suggests Tetra Therapeutics’ BPN14770 Protects Against Memory Loss and Neuronal Atrophy in Alzheimer’s

Partners - Careers - Science - Our Focus - Pipeline - Publications - Clinical Trials - News - Contact - Company - Leadership - Milestones - Partners

of the collaboration is to accelerate the development of an innovative therapeutic for patients in key Asian markets. In exchange for granting Shionogi development

read out of its effects on cognition," he added. BPN14770 is a novel therapeutic agent that works through the PKA-CREB pathway to enhance synaptic action

Presentation of Data from Retrospective Population-Based Study of 56 Million Patients at the 12th Clinical Trials on Alzheimer’s Disease Meeting (CTAD) Tetra

Adaptive Phage Therapeutics Adaptive Phage Therapeutics, Inc

start-up

Access

  • Technologies
  • Core data such as location, employees, revenues
  • Similar and peer companies
  • and more

Web Quotes

to provide an effective therapeutic response to the global rise of multi-drug resistant (MDR) pathogenic bacteria. Learn More Learn More Success Story

Therapeutics Receives Orphan Drug Designation October 29, 2020 News Comments Off on Adaptive Phage Therapeutics Receives Orphan Drug Designation Adaptive

PhageBank phage therapy available to treat multidrug-resistant (MDR) and complicated infections. “This is a promising step toward making phage therapy available

exchange of scientific information concerning APT’s investigational PhageBank™ therapy. The administration of PhageBank for these cases was not within a carefully

giving up, John Haverty turned to internet research. He was aware of phage treatment [the therapeutic use of bacteriophages to treat bacterial infections like

resistant bacterial infections. - APT has made available therapeutic phage treatment to physicians in the Rio Grande Valley of Texas who are treating COVID-19 ...

Infections - A significant increase in mortality has been seen in COVID-19 patients with antibiotic resistant bacterial infections. - APT has made available

journals in the area of infectious disease. He is board-certified in internal medicine (1992, 2006, 2014) and infectious disease (1994, 2006, 2016).

Resistance Congress –CEO to Outline Vision at Global Gathering of Infectious Disease Leaders and Investors– October 30, 2019 08:00 AM Eastern Daylight Time

Adaptive Phage Therapeutics - About APT - COVID-19 Vaccine - Contact - Careers - The Science - Pipeline - Case Studies - News Room - Patient ...

clinical-stage biotechnology company founded to provide an effective therapeutic response to the global rise of multi-drug resistant (MDR) pathogenic bacteria

Adaptive Phage Therapeutics - About APT - COVID-19 Vaccine - Contact - Careers - The Science - Pipeline - Case Studies - News Room - Patient

- Style Guide Clinical Data Manager November 15, 2020 Jobs Comments Off on Clinical Data Manager Position Description: Clinical Data Manager Exciting

Stephanie Holland Director of Clinical Operations Stephanie Holland Ms. Stephanie Holland previously managed Clinical Programs in therapeutic areas covering

Agreement with Researchers at Yale University to Manufacture and Supply Therapeutic Bacteriophage GAITHERSBURG, Maryland, December 12, 2018 – Adaptive Phage

of Life-Threatening Carbapenem Resistant A. baumannii (CRAB) in COVID-19 Patients November 2, 2020 Press Releases Comments Off on PhageBank™ Deployed

Resolve Therapeutics

established

Access

  • Technologies
  • Core data such as location, employees, revenues
  • Similar and peer companies
  • and more

Web Quotes

For Lupus Drug, First Step on the Road to Returns With No IPO, No M&A NewsBy Resolve TherapeuticsMay 17, 2011 Resolve Nabs $2M For Lupus Drug, First Step

For Lupus Drug, First Step on the Road to Returns With No IPO, No M&A NewsBy Resolve TherapeuticsMay 17, 2011 Resolve Nabs $2M For Lupus Drug, First Step

- Our Pipeline - RSLV-132 - Clinical Trials - Science - Nuclease Therapy Platform - Publications - Therapeutic Need - Lupus - Sjögren’s syndrome ...

receptors mobilizes the immune system to eliminate the invading virus. Many patients with lupus and Sjögren’s have circulating RNA-containing autoantigens,

- Our Pipeline - RSLV-132 - Clinical Trials - Science - Nuclease Therapy Platform - Publications - Therapeutic Need - Lupus - Sjögren’s syndrome ...

Trials - Science - Nuclease Therapy Platform - Publications - Therapeutic Need - Lupus - Sjögren’s syndrome - Patient Resources & Advocacy

Announces Completion of Enrollment for Phase 2a Study of RSLV-132 for the Treatment of Lupus NewsBy resolve-adminJuly 22, 2019 Resolve Therapeutics Announces

syndrome. Our Novel Nuclease Platform Resolve is developing a novel treatment to remove pro-inflammatory RNA molecules from the blood of patients with

Resources & Advocacy - News Therapeutic Need LUPUS Lupus is an autoimmune disease that affects five million people worldwide, and primarily impacts women

News Daily Archives: August 17, 2016 Blood-Borne RNA Correlates with Disease Activity and IFN-Stimulated Gene Expression in Systemic Lupus Erythematosus

Skip to content Resolve Therapeutics, LLC. - About Us - Our Company - Management Team - Clinical Advisory Board - Product Candidates - Our Pipeline

Skip to content Resolve Therapeutics, LLC. - About Us - Our Company - Management Team - Clinical Advisory Board - Product Candidates - Our Pipeline

Our Company - Management Team - Clinical Advisory Board - Product Candidates - Our Pipeline - RSLV-132 - Clinical Trials - Science - Nuclease

Our Company - Management Team - Clinical Advisory Board - Product Candidates - Our Pipeline - RSLV-132 - Clinical Trials - Science - Nuclease

Trials - Science - Nuclease Therapy Platform - Publications - Therapeutic Need - Lupus - Sjögren’s syndrome - Patient Resources & Advocacy

evaluating the efficacy and safety of RSLV-132 in patients with lupus. The study will assess 64 patients with active skin disease and elevated RNA-containing

Cognition Therapeutics Cognition Therapeutics, Inc.

established

Access

  • Technologies
  • Core data such as location, employees, revenues
  • Similar and peer companies
  • and more

Web Quotes

oral dose of each of the probe drugs on Day -2 and Day 6 administered as a “drug cocktail: CYP2C19 (omeprazole), CYP2C9 (tolbutamide), CYP2D6 (dextromethorphan)

development and drug discovery. He joined Cognition Therapeutics, Inc. in 2009, where he now leads the company’s efforts to develop small molecule drug candidates

July 28, 2018 McCormick Place, Chicago, Illinois Advances in Alzheimer Therapy (AAT) and AD/PD March 15, 2018 - March 18, 2018 The Centro Congressi Lingotto

of biomarkers of synapse damage or loss in Alzheimer’s disease. Alz Res Therapy 12, 21 (2020) Grundman M, Morgan R, Lickliterd JD, Schneider LS, DeKosky ...

Board - Investors - PipelineMenu Toggle - Pipeline - Alzheimer’s Disease - Dry Age-Related Macular Degeneration - For Patients - Publications

Cognition) study of Elayta™ (CT1812), Cognition’s lead candidate for the treatment of mild-to-moderate Alzheimer’s disease. SPARC (COG0105) is a randomized ...

Board - Investors - PipelineMenu Toggle - Pipeline - Alzheimer’s Disease - Dry Age-Related Macular Degeneration - For Patients - Publications ...

Pipeline - Alzheimer’s Disease - Dry Age-Related Macular Degeneration - For Patients - Publications and References - Resources - News & EventsMenu Toggle

normal cognitive performance in aged transgenic mouse models of AD. Chronic treatment of aged transgenic mice with efficacious doses of CT1812 significantly

Releases Cognition Therapeutics Appoints Brett P. Monia to its Board of Directors October 27, 2020 Read More » Cognition Therapeutics Elucidates Genetic ...

Publication Analyzing Biomarkers of Synapse Damage or Loss to Support Future Therapeutic Development Efforts in Alzheimer’s Disease March 17, 2020 Read More »

which bind to receptors and disrupt key cellular processes. Cognition Therapeutics’ lead candidate, CT1812, is designed to displace toxic protein oligomers

We deeply thank the patients, families, clinical researchers, hospitals and clinics that participate in clinical trials that are designed to test our lead ...

Degeneration - For Patients - Publications and References - Resources - News & EventsMenu Toggle - Press Releases - Events For Patients and Their Families

Cognition Therapeutics Expands Industry-Leading Expertise in Research and Clinical Use of Biomarkers of Alzheimer’s Disease —Drs. Kaj Blennow, John Harrison

biological changes caused by this mutation, with the aim of developing a therapeutic that replicates those conditions. Cognition scientists conducted a series

Use detailed technology terms.

Only spotfolio allows for searching with detailed technology terms, as we provide you with all topics that technology companies talk about.

Use Cases

Register now

Why Technology Scouting?

Technology scouting is the basis for your innovation management, identifies new technological developments as early as possible and protects you from disruptive business models.

Identify technology partners

Boost your market research

Look beyond major players

Build long and short lists

Collect technology leaders, providers, start ups and potential new partners in lists via simple tagging to take further steps with your team.